View Post

Jefferson researcher discovers a population of bone cells that subdues cancer

In In The News by Barbara Jacoby

Source: jefferson.edu From: news-medical.net In breast cancer, there are cases of women and men whose cancer returns in their bones 20-30 years after they were treated for their primary disease and thought they were cancer-free. This phenomenon always puzzled Jefferson researcher Karen Bussard, PhD. How is it possible that breast cancer cells from a primary tumor are able to reach …

View Post

ASCO 2019: Test All Triple Negative Breast Cancer Patients for PD-L1

In Clinical Trials by Barbara Jacoby

From: physiciansweekly.com Latest analysis from IMpassion trial confirms need for testing One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies, and that message came through loud and clear during an oral abstract session devoted to treatment of …

View Post

IU Precision Health Initiative has dramatic results for triple negative breast cancer patient

In Clinical Trials by Barbara Jacoby

By: Christine Drury From: iu.edu Five years ago, Jackie Stephens rolled over in bed and felt a horrible pain in her right breast. A subsequent mammogram revealed a large lump in her right breast and two smaller ones. Her diagnosis: triple negative breast cancer. Stephens’ oncologist prescribed a treatment regimen of chemotherapy, a lumpectomy and radiation. When her treatment was …

View Post

Harbor Branch Oceanographic Institute researches ‘promising’ triple-negative breast cancer treatment

In In The News by Barbara Jacoby

By: Meghan McRoberts From: wptv.com Researchers at FAU’s Harbor Branch Oceanographic Institute have been awarded a large grant to look into the chance that a chemical released by sea sponges in various oceans could treat an aggressive form of breast cancer. “I find it really, really promising,” said Associate Research Professor, Dr. Esther Guzman. She is leading the research project …

View Post

Investigators Slow Growth by Starving Triple-Negative Breast Cancer Cells

In Clinical Trials by Barbara Jacoby

By: Jennifer Nesse From: specialtypharmacytimes.com Investigators from the Brazilian Biosciences National Laboratory have developed a strategy for slowing the growth of triple-negative breast cancer (TNBC) that involves cutting cancerous cells off from vital food sources. The study, published in the Journal of Biological Chemistry, focused on TNBC tumors, which often lack estrogen progesterone receptors and human epidermal growth factor receptor …

View Post

FDA grants fast track designation to leronlimab for metastatic triple-negative breast cancer

In Clinical Trials by Barbara Jacoby

From: healio.com The FDA granted fast track designation to leronlimab for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer. Leronlimab (PRO 140, CytoDyn Inc.) is an investigational humanized IgG4 monoclonal antibody that blocks CCR5, a cellular receptor believed to play key roles in tumor invasion and metastasis. Agents that block CCR5 have …

View Post

Forbius Announces First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

In Clinical Trials by Barbara Jacoby

From: scnow.com Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced today that the first patient has been dosed in a Phase 2a triple negative breast cancer (TNBC) clinical trial with AVID100, a novel, tumor-specific anti-epidermal growth factor receptor (EGFR) antibody-drug conjugate (ADC). Approximately 20% of patients with TNBC have tumors that highly …

View Post

Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Intensity Therapeutics Inc From: globenewswire.com Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s development program evaluating INT230-6 for the treatment of patients with relapsed …

View Post

Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy

In In The News by Barbara Jacoby

Source: University of Texas M. D. Anderson Cancer Center From: eurekalert.org Study finds that resistant cells become vulnerable to MD Anderson-developed targeted therapy Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on …

View Post

Gold nanoparticle delivery of microRNA impairs metastasis in triple-negative breast cancer

In In The News by Barbara Jacoby

By: Weill Cornell Medical College From: medicalxpress.com Weill Cornell Medicine researchers have shown that giving mice with triple-negative breast cancer therapeutic microRNA (miRNA) in a protective gold nanoparticle results in significantly less spreading of cancer to the lung. Triple-negative breast cancer is a highly aggressive, difficult-to-treat form of the disease, with a high rate of metastatic recurrence. miR-708 is a …